Period:
Draw Mode:
| Volume | 0 |
|
|||||
| News | - | ||||||
| Day High | Low High |
||||||
| Day Low | |||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Century Therapeutics Inc | IPSC | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| 0.00 | 0.0% | 3.46 | 04:00:00 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 3.46 |
| Trades | Volume | Avg Volume | 52 Week Range |
|---|---|---|---|
| 0 | 0 | - | 3.40 - 14.00 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| - | 0 | $ 3.46 | USD |
Century Therapeutics Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| $ 204.73M | 59.17M | 12.84M | $ 5.20M | $ - | -2.28 | 100.00 |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | $ - | - | 2.65M | 3.20% |
Century Therapeutics News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical IPSC Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 3.82 | 3.82 | 3.40 | 3.55 | 163,441 | -0.36 | -9.42% |
| 1 Month | 4.50 | 5.3399 | 3.40 | 4.18 | 202,123 | -1.04 | -23.11% |
| 3 Months | 4.99 | 5.3399 | 3.40 | 4.46 | 218,517 | -1.53 | -30.66% |
| 6 Months | 10.10 | 11.95 | 3.40 | 5.89 | 160,811 | -6.64 | -65.74% |
| 1 Year | 12.53 | 14.00 | 3.40 | 7.58 | 132,553 | -9.07 | -72.39% |
| 3 Years | 19.50 | 32.899 | 3.40 | 14.59 | 147,304 | -16.04 | -82.26% |
| 5 Years | 19.50 | 32.899 | 3.40 | 14.59 | 147,304 | -16.04 | -82.26% |
Century Therapeutics Description
| Century Therapeutics Inc is a biotechnology company developing transformative allogeneic cell therapies to create products for the treatment of both solid tumor and hematological malignancies with a significant unmet medical need. It is assembling a portfolio of allogeneic iNK and iT cell therapy product candidates across solid tumor and hematological malignancies. |